(Q33978357)

30 July 2017

1 reference

title

Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. (English)

1 reference

30 July 2017

0 references

1 reference

venous thromboembolism

1 reference

B A Hutten

1

1 reference

30 July 2017

M H Prins

series ordinal

2

1 reference

30 July 2017

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

30 July 2017

published in

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

CD001367

1 reference

Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001367

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001367

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001367

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001367

Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001367

Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001367

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001367

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001367

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001367

10.1002/14651858.CD001367

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference